Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108
Recruiting now Phase 1 NCT07153172
Run by Novo Nordisk A/S · for 18 and older · All sexes · accepts healthy volunteers
What this study is about
The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last until visit 21.
Who can join (things the study team will check)
✅ You may be able to join if…
- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- Male or female (sex at birth).
- Age 18 years or above at the time of signing the informed consent.
- Previously dosed with INV-347 in study INV-CL-108 and with measurable INV-347 concentration in plasma at enrolment [above lower limit of qualification (LLOQ) of 0.5 nanogram per milliliter (ng/mL)].
Where this trial is running
- Syneos Health Clinique, Québec, Canada
Who to contact
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07153172.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.